89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. SPY
4. ICLR
5. JPM
6. LAES
7. FUL
8. NNE
9. IONS
10. IBM

Go back to 89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

August 5, 2024 4:05 PM EDT

The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirrhosis (F4) are enrolling patients

Phase 3 ENTRUST trial for patients with severe hypertriglyceridemia (SHTG) continues to enroll patients and topline data is expected in 2025

SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the second quarter ended June 30,... More

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

August 5, 2024 8:00 AM EDT

SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024.

We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors, said Rohan... More